A number of novel drugs for DN treatment have been shown to affect the expression of p-p38 MAPK and TGF-β1 to improve renal tubulointerstitial fibrosis in experimental animals with DN (Fujita et al., 2004; Cheng et al., 2013; Jiang et al., 2017; Wang et al., 2019a). The gene discussed is TGFB1; the disease is liver dysplastic nodule.